Extremely Preterm Respiratory Outcome Cohort
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Dec 4, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The Extremely Preterm Respiratory Outcome Cohort study is looking at how breathing problems affect very premature infants who are born before 29 weeks of pregnancy. Researchers want to understand how different factors, like breathing difficulties right after birth, the use of certain medications, and nutrition in the hospital, influence long-term respiratory health. They are also interested in how these infants grow and develop in their early years. The goal is to find ways to improve treatments and prevent breathing issues for these vulnerable babies.
To be part of this study, infants must be born at less than 29 weeks of pregnancy, and their parents need to give permission within a week after birth. Unfortunately, babies who have severe heart defects or structural problems with their breathing system cannot join. Participants will be followed from birth up to 24 months to track their breathing and overall development. This research is important as it aims to improve the lives of infants who start life very early.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Infants born at gestational age less than 29 weeks with cohort consent obtained within 7 days of birth
- Exclusion Criteria:
- • death within 3 days of birth
- • severe structural heart defects
- • structural abnormalities in the upper airway, lungs, or chest
- • congenital anomalies that may impact cardiopulmonary function
- • follow-up is difficult until 24 months of age
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Seung Han Shin, MD, PhD
Principal Investigator
Seoul National University Children's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported